companies developing glp 1 drugs GLP-1 Market Industry Trends and Global Forecasts 2024-2035: Over 150 GLP-1 Drug Candidates in Development for Multiple Indications, Type 2 Diabetes and Obesity Drive GLP-1 Drug Development Boom 2 Companies Poised to Capitalize

Conway B, Miller RG, Costacou T, et al

The care paradigm is starting to shift, with the understanding that its beneficial to treat metabolic health conditions before they progress to an advanced stage. The team hopes this new data can help physicians better understand and identify patients who are less likely to access obesity treatment, with challenges ranging from difficulty in obtaining care from obesity medicine practitioners to lack of formulary coverage for weight-management medications

doi: 10.2337/dc13-0354

This means they have not been formally assessed for safety, efficacy, or quality by the New Zealand's medicines regulator (6)

Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: a review